July 23, 2013
1 min read

Targeted drug delivery with liposome technology reduces IOP, maintains results

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

VANCOUVER, British Columbia — Subconjunctival injection of a liposome-latanoprost agent using nanotechnology reduced IOP in patients with glaucoma, and results were sustained through 3 months, a speaker said here.

“Having sustained delivery is a ‘no-brainer.’ There’s more efficient drug use. There’s less drug wastage. The drug is independent of the patient’s compliance … You have targeted delivery of the drug to the right place, and you have round-the-clock delivery so you’re not worried about any loss of effect,” Tina T. Wong, FRCOphth, FRCSEd, PhD, said at the World Glaucoma Congress.

Tina T. Wong, FRCOphth, FRCSEd, PhD

Tina T. Wong

In the open-label, single-arm, phase 1 study, 100 µL of the combination agent, LipoLat, was injected in the superior bulbar conjunctiva of six patients with either ocular hypertension or very mild primary open-angle glaucoma. All of the patients were on monotherapy and had an IOP between 22 mm Hg and 36 mm Hg after wash-out. IOP was measured after the injection at 1 hour, 7 days, 14 days, and at 1, 2 and 3 months, Wong said.

IOP reduction of up to about 10 mm Hg was sustained at 3 months, Wong said. No patient had discomfort due to subconjunctival injection; redness, pain and burning; or anterior chamber activity. Two patients experienced dry eyes, and lubricants were prescribed.

“We showed that LipoLat is well-tolerated without any substantial safety issues,” Wong said. Wong continues to follow-up patients and said that the pressure-lowering effects have continued to 5 months.

A multicenter, phase 2 trial is planned.

Disclosure: Wong is co-inventor and named patent holder for the product presented in the presentation, with sponsorship by Allergan.